Patents Assigned to Upjohn
  • Quinuclidine-substituted heteroaryl moieties for treatment of disease
    Patent number: 6599916
    Abstract: The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which &agr;7 is known to be involved.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: July 29, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Jason K. Myers, Bruce N. Rogers, Vincent E. Groppi, Jr., David W. Piotrowski, Alice L. Bodnar, Eric Jon Jacobsen, Jeffrey W. Corbett
  • Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
    Patent number: 6596697
    Abstract: According to the invention there is provided a sterile, pyrogen-free, ready-to-use solution of an anthracycline glycoside, especially doxorubicin, which consists essentially of a physiologically acceptable salt of an anthracycline glycoside dissolved in a physiologically acceptable solvent therefor, which has not been reconstituted from a lyophilizate and which has a pH of from 2.5 to 6.5. The solution of the invention is particularly advantageous for the administration by injection of the anthracycline glycoside drugs, e.g. doxorubicin, in the treatment of both human and animal tumors.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: July 22, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Gaetano Gatti, Diego Oldani, Giuseppe Bottoni, Carlo Confalonieri, Luciano Gambini, Roberto De Ponti
  • Inhibitors of &agr;4&bgr;1 mediated cell adhesion
    Patent number: 6596752
    Abstract: The present invention relates to small molecules according to the formula [I]: which are potent inhibitors of &agr;4&bgr;1 mediated adhesion to either VCAM or CS-1 and which can be used for treating or preventing &agr;4&bgr;1 adhesion mediated conditions in a mammal such as a human.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: July 22, 2003
    Assignees: Tanabe Seiyaku Co., Ltd., Pharmacia & Upjohn Company
    Inventors: Thomas J. Lobl, Bradley R. Teegarden, Alexander Polinsky, Gilbert M. Rishton, Masafumi Yamagishi, Steven Tanis, Jed F. Fisher, Edward W. Thomas, Robert A. Chrusciel
  • Anti-tumor synergetic composition
    Patent number: 6593303
    Abstract: There are provided the combined use of 4-demethoxy-3′-deamino-3′-aziridinyl-4′-methansulfonyl daunorubicin or 4-demethoxy-N,N-bis(2-chloroethyl)-4′-methansulfonyl daunorubicin and an anti-neoplastic anti-mitotic compound and/or a platinum derivative in the treatment of tumors, as well as in the prevention or treatment of metastasis or in the treatment of tumors by inhibition of angiogenesis.
    Type: Grant
    Filed: August 22, 2001
    Date of Patent: July 15, 2003
    Assignee: Pharmacia & Upjohn, S.p.A.
    Inventors: Cristina Geroni, Marina Ripamonti, Michele Caruso, Antonino Suarato
  • PROCESS TO PRODUCE 3-CARBON AMINO ALCOHOL SALTS
    Publication number: 20030130509
    Abstract: The present invention includes a number of novel intermediates such as the (S)-secondary alcohol of formula (VIIIA)
    Type: Application
    Filed: January 28, 2003
    Publication date: July 10, 2003
    Applicant: Pharmacia & Upjohn Company
    Inventor: Bruce Allen Pearlman
  • Compounds and methods for diagnosing and treating amyloid-related conditions
    Patent number: 6589504
    Abstract: The invention provides methods for diagnosing and treating amyloid-related conditions and compounds useful for the same. The invention provides for detecting, imaging, monitoring, diagnosing, and treating conditions characterized by the binding or aggregation of amyloid fibrils. More particularly, the invention relates to using quinolinehydrazone compounds for diagnosing and treating amyloidotic conditions and also as an antioxidant.
    Type: Grant
    Filed: September 22, 2000
    Date of Patent: July 8, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Thomas J. Raub, Geri A. Sawada, Steven P. Tanis, Gregory J. Fici, Allen Edwin Buhl, Donald Bainbridge Carter, Tiziano Bandiera, Jacqueline Lansen, Cesare Pellerano, Luisa Savini
  • Method for identifying compounds that modulate the interaction of amyloid beta or its aggregates with a voltage gated sodium channel
    Patent number: 6589747
    Abstract: Among other things, assays and methods of diagnosis and treatment of disease (e.g., Alzheimer's disease) based on the surprising observation of an interaction between amyloid &bgr; or its aggregates with the sodium channel are provided. In particular, methods to identify compounds that modulate this interaction are provided, as well as methods of diagnosis and treatment that are based on this interaction.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: July 8, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Kai S. Lee, Xiao-Dong Sun, Bruce M. Taylor, Dennis E. Epps, Allen E. Buhl
  • Method of treating and preventing migraine headaches
    Patent number: 6589965
    Abstract: A method of preventing or treating migraine headaches is disclosed comprising administering to a person in need thereof a pharmacologically effective amount of specific substituted phenylazacycloalkanes. These compounds can treat or prevent symptoms associated with migraine headaches and yet avoid undesirable side affects associated with conventional migraine treatment compositions. Additionally, other agents used to treat migraine headaches can be used in combination therewith.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: July 8, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventor: Kjell A. Svensson
  • Purification of somatotropin from transformed microorganisms
    Patent number: 6586575
    Abstract: This invention discloses a commercially advantageous process for extraction and purification of protein from microorganisms. The initial steps of the process are useful for purifying many insoluble proteins while later steps are designed to renature denatured somatotropins produced by transformed microorganisms. The process is especially useful for purifying recombinantly-produced bovine somatotropin.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: July 1, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Timothy W. Evans, Mark W. Knuth
  • Substituted azepino[4,5b]indoline derivatives
    Patent number: 6586421
    Abstract: The invention provides compounds of Formula (I): wherein R1-R4, p and q have any of the values described in the specification, as well as pharmaceutical salts thereof, and pharmaceutical compositions containing such compounds or salts. The compounds and salts are 5-HT ligands and are useful for treating diseases, disorders, and/or conditions in a mammal wherein activity of a 5-HT receptor is implicated. The compounds and salts are particularly useful for treating diseases of the central nervous system.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: July 1, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Kristine E. Frank, Brad A. Acker, Michael D. Ennis, Jed F. Fisher, Jian-min Fu, Eric Jon Jacobsen, William W. McWhorter, Jr., Jeanette K. Morris, Donald Joseph Rogier
  • Bis-arylsulfones
    Patent number: 6586592
    Abstract: The present invention provides pharmaceutically active compounds useful for the treatment of diseases or disorders of the central nervous system.
    Type: Grant
    Filed: October 2, 2001
    Date of Patent: July 1, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Eric Jon Jacobsen, Stephen J. King, Kalpana M. Merchant
  • Process to prepare (5R)-(methylamino)-5, 6-dihydro-4H-imidazo[4,5,1-ij]-quinolin-2(1H)-one
    Patent number: 6586595
    Abstract: The present invention is an improved prosess to prepare (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one the compound of formula (VII)
    Type: Grant
    Filed: August 22, 2001
    Date of Patent: July 1, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventor: Peter Guillaume Marie Wuts
  • Treatments for nervous disorders
    Patent number: 6586427
    Abstract: This patent application describes the treatment of Addictive disorders, Psychoactive Substance Use disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco addiction and or Nicotine addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.
    Type: Grant
    Filed: August 13, 2001
    Date of Patent: July 1, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Fred Hassan, John Michael McCall, Duncan Paul Taylor, Philip F. Von Voigtlander, Erik Ho Fong Wong
  • Substituted azepino[4,5b]indole derivatives
    Patent number: 6583135
    Abstract: Disclosed are compounds of Formula (I): wherein R1-R4, p and q have any of the values described in the specification, as well as pharmaceutical salts thereof, and pharmaceutical compositions containing such compounds or salts. The compounds and salts are 5-HT ligands and are useful for treating diseases, disorders, and/or conditions in a mammal wherein activity of a 5-HT receptor is implicated. The compounds and salts are particularly useful for treating diseases of the central nervous system.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: June 24, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Kristine E. Frank, Brad A. Acker, Michael D. Ennis, Jed F. Fisher, Jian-min Fu, William W. McWhorter, Jr., Jeanette K. Morris, Donald Joseph Rogier, Eric Jon Jacobsen
  • Use of fluorescence correlation spectroscopy to identify compounds that bind to target species under isothermal denaturing conditions
    Patent number: 6582907
    Abstract: The present invention provides a method for identifying a test compound that binds to a target species. The method includes: incubating at least one test mixture under isothermal denaturing conditions, each test mixture comprising at least one test compound, and at least one target species, wherein the isothermal denaturing conditions are effective to cause at least a portion of the target species to denature to a measurable extent; detecting a denaturation signal of each target species in the presence of the at least one test compound by a change in the diffusion properties of the target molecule using fluorescence correlation spectroscopy; and comparing the denaturation signal of each target species in the presence of at least one test compound with a denaturation signal of the same target species in the absence of the at least one test compound under the same isothermal denaturing conditions.
    Type: Grant
    Filed: December 9, 1999
    Date of Patent: June 24, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Dennis E. Epps, Paul K. Tomich, Ferenc J. Kezdy, Charles K. Marschke
  • Bis-arylsulfones
    Patent number: 6579870
    Abstract: The present invention provides pharmaceutically active compounds useful for the treatment of diseases or disorders of the central nervous system.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: June 17, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Eric Jon Jacobsen, Stephen J. King
  • Crystalline thiazine oxazolidinones
    Publication number: 20030109525
    Abstract: The present invention provides crystals including a thiazine oxazolidinone. Thiazine oxazolidinones are useful as antimicrobials.
    Type: Application
    Filed: July 10, 2002
    Publication date: June 12, 2003
    Applicant: PHARMACIA & UPJOHN COMPANY
    Inventors: Meredith L. Greene, Jiong J. Chen, Mark T. Maloney, Cuong V. Lu
  • Process to prepare (2S)-2-(dipropylamino)-6-ethoxy-2,3-dihydro-1H-indene-5-carboxamide
    Patent number: 6576769
    Abstract: The present invention is a process, including intermediates, to produce (2S)-2-dipropylamino)-6-ethoxy-2,3-dihydro-1H-indene-5-carboxamide which is a useful pharmaceutical agent.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: June 10, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Jiong Jack Chen, Arthur Glenn Romero, Styrbjorn Bystrom
  • Antitumor therapy comprising distamycin derivatives
    Patent number: 6576612
    Abstract: The present invention relates to an administration schedule comprising the intravenous administration of a &agr;-halogen-acryloyl distamycin derivative of formula (I) wherein R is a bromine or chlorine atom; or a pharmaceutically acceptable salt thereof. The above administration allows the treatment of a variety of tumors in mammals.
    Type: Grant
    Filed: October 2, 2000
    Date of Patent: June 10, 2003
    Assignees: Pharmacia Italia S.p.A., Pharmacia & Upjohn Company
    Inventors: Camilla Fowst, Franzanne Vreeland, Maria Cristina Rosa Geroni
  • Pyrrole substituted 2-indolinone protein kinase inhibitors
    Patent number: 6573293
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: June 3, 2003
    Assignees: Sugen, Inc., Pharmacia & Upjohn Co.
    Inventors: Peng Cho Tang, Todd A. Miller, Xiaoyuan Li, Li Sun, Chung Chen Wei, Shahrzad Shirazian, Congxin Liang, Tomas Vojkovsky, Asaad S. Nematalla, Michael Hawley